l-Carnosine As an Adjunctive Therapy to Risperidone in Children with Autistic Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial
Randomised controlled trialHumansWith risperidone (both groups)
This study tested carnosine together with risperidone (both groups). Its results cannot be assigned to carnosine alone. More combination studies.
- Design
- Randomised controlled trial
- Subjects
- 70 drug-free children aged 4 to 12 years with autism spectrum disorder (DSM-5) and ABC-C irritability subscale score of 12 or more
- Dose used in the study
- 800 mg carnosine per day in two divided doses, added to risperidone up to 2 mg per day
- Duration
- 10 weeks
- What was measured
- Aberrant Behavior Checklist-Community subscales at baseline, week 5 and week 10. Primary outcome: irritability subscale. Extrapyramidal symptoms and side effects.
What the authors reported
No significant difference between groups on the irritability subscale (primary outcome). The hyperactivity/noncompliance subscale improved more with carnosine (p = 0.044). Lethargy, stereotypy and inappropriate speech subscales did not differ. Side effects did not differ between groups.
Limits of this study
Primary outcome negative. Ten weeks. Conducted in Iran. All children also took risperidone. Full text not read.
Source
PubMed 29027815 · doi:10.1089/cap.2017.0026
Entry checked against PubMed abstract (E-utilities) on 2026-10-19. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.